Details for New Drug Application (NDA): 040320
✉ Email this page to a colleague
NDA 040320 describes TAPAZOLE, which is a drug marketed by King Pharms and King Pharms Llc and is included in two NDAs. Additional details are available on the TAPAZOLE profile page.
The generic ingredient in TAPAZOLE is methimazole. There are three drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the methimazole profile page.
The generic ingredient in TAPAZOLE is methimazole. There are three drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the methimazole profile page.
Summary for 040320
| Tradename: | TAPAZOLE |
| Applicant: | King Pharms Llc |
| Ingredient: | methimazole |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 040320
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Mar 31, 2000 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Mar 31, 2000 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
